Literature DB >> 11981111

Right atrial thrombus treated successfully with abciximab and heparin.

A C Borges1, R K Reibis, M Claus, G Baumann.   

Abstract

We report here a case of right atrial thrombus diagnosed by echocardiography in a 25-year-old female patient with Hodgkin's disease receiving chemotherapy and heparin. After 24 hours therapy with the glycoprotein IIb/IIIa receptor antagonist (abciximab) with concomitant heparin the complete dissolution of the thrombus could be demonstrated by transesophageal echocardiography. To our knowledge this case represents the first use of abciximab in right atrial thrombosis.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11981111     DOI： 10.1023/a:1015235326994

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


  17 in total

Review 1.  Acute pulmonary embolism 1: pathophysiology, clinical presentation, and diagnosis.

Authors:  M Riedel
Journal:  Heart       Date:  2001-02       Impact factor: 5.994

2.  Incidence and management of catheter occlusion in implantable arm ports: results in 391 patients.

Authors:  C J Whigham; M C Greenbaum; R G Fisher; C J Goodman; J I Thornby; J W Thomas
Journal:  J Vasc Interv Radiol       Date:  1999-06       Impact factor: 3.464

3.  Free-floating thrombi in the right heart: diagnosis, management, and prognostic indexes in 38 consecutive patients.

Authors:  L Chartier; J Béra; M Delomez; P Asseman; J P Beregi; J J Bauchart; H Warembourg; C Théry
Journal:  Circulation       Date:  1999-06-01       Impact factor: 29.690

4.  Abciximab readministration: results of the ReoPro Readministration Registry.

Authors:  J E Tcheng; D J Kereiakes; A M Lincoff; B S George; N S Kleiman; D C Sane; D B Cines; R E Jordan; M A Mascelli; M A Langrall; L Damaraju; A Schantz; M B Effron; G A Braden
Journal:  Circulation       Date:  2001-08-21       Impact factor: 29.690

5.  Acute thromboscintigraphy with (99m)Tc-apcitide: results of the phase 3 multicenter clinical trial comparing 99mTc-apcitide scintigraphy with contrast venography for imaging acute DVT. Multicenter Trial Investigators.

Authors:  R Taillefer; S Edell; G Innes; J Lister-James
Journal:  J Nucl Med       Date:  2000-07       Impact factor: 10.057

6.  Right atrial thrombi are related to indwelling central venous catheter position: insights into time course and possible mechanism of formation.

Authors:  D Gilon; D Schechter; A J Rein; Z Gimmon; R Or; Y Rozenman; S Slavin; M S Gotsman; A Nagler
Journal:  Am Heart J       Date:  1998-03       Impact factor: 4.749

7.  [Infectious and non-infectious complications of tunneled central catheters in hematologic patients].

Authors:  C Albo López; D López Rodríguez; M I Constenla Camba; A Jimenéz Blanco; L F Araujo; J García-Medina
Journal:  Sangre (Barc)       Date:  1999-06

Review 8.  Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications.

Authors:  S A Cohen; M Trikha; M A Mascelli
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

9.  Thrombosis and embolism in long-term central venous access for parenteral nutrition.

Authors:  C M Dollery; I D Sullivan; O Bauraind; C Bull; P J Milla
Journal:  Lancet       Date:  1994-10-15       Impact factor: 79.321

10.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.

Authors: 
Journal:  N Engl J Med       Date:  1994-04-07       Impact factor: 91.245
View more
  2 in total

1.  Large atrial thrombus at unusual site: masquerading atrial myxoma.

Authors:  Yadvinder Singh; Jayashree Kharge; Raghu Thagachagere Ramegowda; Manjunath Cholenahally Nanjappa
Journal:  J Thromb Thrombolysis       Date:  2013-07       Impact factor: 2.300

2.  Right atrial thrombus formation associated with central venous catheters utilization in hemodialysis patients.

Authors:  Mohammad K Ghani; Fernando Boccalandro; Ali E Denktas; Eddy Barasch
Journal:  Intensive Care Med       Date:  2003-07-25       Impact factor: 17.440
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.